Alcon Gains FDA Approval for LADAR6000(TM) Excimer Laser and Wavefront-Guided Hyperopia

Alcon, Inc. (NYSE:ACL) announced today that the U.S.Food & Drug Administration (FDA) has approved its LADAR6000(TM)Excimer Laser with high speed ablation for use in LASIK and PRKrefractive surgery. With a 50% faster ablation rate than previousLADARVISION(R) platforms, the LADAR6000(TM) laser significantlydecreases surgical time, especially in higher refractive correctionranges, and results in less exposure of the corneal flap. TheLADAR6000(TM) laser, developed on a flexible platform to allow forfuture upgrades, also includes a number of enhancements that aredesigned to improve overall system performance, ease of use, andpatient flow.

The FDA also granted the industry's broadest wavefront-guidedhyperopic indication for Alcon's CUSTOMCORNEA(R) procedure on both theLADAR6000(TM) laser and the LADARVision(R) 4000 System. With thisapproval, surgeons are able to treat hyperopia and hyperopicastigmatism (+0.75D to +5.00D sphere with up to -3.00D cylinder) inaddition to the current range for myopia and myopic astigmatism.

About Alcon

Alcon, Inc. is the world's leading eye care company with sales of$4.4 billion in 2005. Alcon, which has been dedicated to theophthalmic industry for more than 50 years, develops, manufactures andmarkets pharmaceuticals, surgical equipment and devices, contacts lenscare solutions and other vision care products that treat diseases,disorders and other conditions of the eye. For more information onAlcon, Inc., visit the Company's Web site at www.alconinc.com.

Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within themeaning of the Private Securities Litigation Reform Act of 1995,relating principally to our ability to successfully market and sellthe LADAR6000(TM) laser for wavefront-guided laser eye surgery. Thesestatements involve known and unknown risks, uncertainties and otherfactors which may cause our actual results, performance orachievements to be materially different from any future results,performances or achievements expressed or implied by ourforward-looking statements. These statements reflect the views of ourmanagement as of the date of this press release with respect to futureevents and are based on assumptions and subject to risks anduncertainties. Given these uncertainties, you should not place unduereliance on these forward-looking statements. You should read thispress release with the understanding that our actual future resultsmay be materially different from what we expect. Except to the extentrequired under the federal securities laws and the rules andregulations promulgated by the Securities and Exchange Commission, weundertake no obligation to publicly update or revise any of theseforward-looking statements, whether to reflect new information orfuture events or circumstances or otherwise.